In plain terms: Saffron (Crocus sativus) has some human trial evidence supporting it, but the evidence is not yet strong enough for EBL to call it established. It is worth knowing about and worth discussing with your clinician.
Saffron (Crocus sativus)
The evidence as the record states it
Toth et al. (Planta Medica, 2019; PMID 30036891) and Shafiee et al. (Nutrition Reviews, 2025; PMID 38913392): meta-analyses of randomized trials: saffron improved mild-to-moderate depression, in some analyses comparable to SSRIs. Grade B: multiple RCTs and meta-analyses, though trials are mostly small.
Why Grade B and not Grade A
Grade B reflects moderate human evidence -- typically a single strong trial, multiple smaller trials, or surrogate endpoint data without hard clinical outcome replication. To reach Grade A, Saffron (Crocus sativus) would require at least one additional independent randomized trial demonstrating a hard clinical endpoint or objectively measured functional outcome in a comparable population.
What would move this grade
An independent randomized trial demonstrating a hard clinical endpoint -- mortality, major adverse event, or objectively confirmed functional improvement -- in an adequately powered sample, with results independently replicated, would support Grade A.
How this was studied
Form: Oral saffron (Crocus sativus) at pharmacological doses, compared with placebo or antidepressant drugs (Toth 2019, PMID 30036891); saffron compared with SSRIs (Shafiee 2025, PMID 38913392). · Dose: not stated in the cited papers · Population: Patients with mild to moderate depression, in 11 randomized trials (9 pooled) (Toth 2019, PMID 30036891); adults with depression or anxiety in trials comparing saffron with SSRIs, 8 trials for depression and 4 for anxiety (Shafiee 2025, PMID 38913392). · Duration: not stated in the cited papers